Report of Foreign Issuer (6-k)
April 18 2018 - 6:09AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For
the Month of April 2018
001-37353
(Commission
File Number)
BIONDVAX
PHARMACEUTICALS LTD.
(Exact
name of Registrant as specified in its charter)
14
Einstein St.
Ness
Ziona
Israel
74036
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover
Form 20-F
or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T
Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T
Rule 101(b)(7): ____
Indicate
by check mark whether by furnishing the information contained in this Form, the registrant is also thereby
furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If
“Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-N/A
On
April 11, 2018, BiondVax Pharmaceuticals Ltd. (hereinafter, the “Registrant”, the “Company”, or “BiondVax”)
issued a press release announcing the enrollment of the first participant in an NIH-Sponsored Phase 2 Clinical Trial of M-001,
BiondVax’s universal flu vaccine candidate, in the United States. A copy of this press release is attached hereto as Exhibit
99.1 and is incorporated by reference.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
BiondVax
Pharmaceuticals Ltd.
|
|
|
|
Date:
April 18, 2018
|
By:
|
/s/
Ron Babecoff
|
|
|
Ron
Babecoff
|
|
|
Chief
Executive Officer
|
2
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Aug 2024 to Sep 2024
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Sep 2023 to Sep 2024